FDA's worries about Abecma's early death rates and the decis...

FDA's worries about Abecma's early death rates and the decision to hold an advisory meeting instead of approving its use have hit 2seventy and Bristol Myers Squibb's stocks. Abecma's future and its effect on the stocks hinge on the FDA meeting's outcome.